石明 - 中山大学 - 肿瘤防治中心

研究领域

主要从事肝癌的综合治疗，包括：外科治疗、介入治疗、靶向治疗、免疫治疗等，及相应基础研究。近年来致力于优化中晚期肝癌综合治疗的策略，力求提高疗效，改善患者生活质量。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1)OuYang HY, Xu J, Luo J, Zou RH, Chen K, Le Y, Zhang YF, Wei W, Guo RP, Shi M（通讯作者）. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology 2016; 63(4): 1227-39. (IF 11.1) 2)Shi M（通讯作者）, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013;105(1):59-68. (IF 12.6) 3)Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007; 245:36-43.(IF:8.3) 4)Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M（通讯作者）. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple and resectable hepatocellular carcinoma: a prospective non-randomized analysis. Radiology 2011; 259:286-95. (IF 6.9) 5)Zhang YF, Guo RP, Zou RH, Shen JX, Wei W, Li SH, OuYang HY, Zhu HB, Xu L, Lao XM, Shi M（通讯作者）. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol 2016; 26(7): 2078-88. (IF 4.0) 6)Shi M, Chen MS, Sekar K et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer 2014; 50: 928-936. (IF 5.4) 7)Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M（共同通讯作者）, Guo RP: Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer 115:1039-1047, 2016 （IF：5.57） 8)Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M（通讯作者）. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol, 2011; 18:413-20. (IF 3.9) 9)Zhang YF, Guo RP, OuYang HY, Shen JX, Zhao J, Tan GS, Le Y, Wei W, Shi M（通讯作者）: Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. Liver Int 2016;36:1516-24.（IF：4.47） 10)He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M（通讯作者）. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer 2017; 36(1): 83. 11)He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M（通讯作者）. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol 2018.